Latest Idiopathic thrombocytopenic purpura Stories
18 patient advocacy and health care professional groups join with Congressional sponsors Reps.
First and Only Approved Platelet Producer in Europe Represents New Treatment Approach for Serious Chronic Autoimmune Disorder ZUG, Switzerland, Feb.
SHENYANG, China, Jan.
SAN FRANCISCO, Dec. 8 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP).
SAN FRANCISCO, Dec.
Protalex, Inc. (OTCBB:PRTX) today announced that Steven H. Kane, President and Chief Executive Officer, will present at the upcoming Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 3:40 p.m. Eastern Time.
New funding is available for nurses seeking to improve treatment of patients with auto-immune diseases and cancer, through a series of grants being awarded by the DAISY Foundation. Applications are now being accepted for the foundation's J.
Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc.
Under a new program introduced by Talecris Biotherapeutics, patients who regularly use Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) may be able to receive continuing treatment in the event of a lapse in private insurance coverage.
- A transitional zone between two communities containing the characteristic species of each.